Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Int J Cancer. 2019 Feb 23;145(7):1798–1808. doi: 10.1002/ijc.32154

Table 5.

Best overall response by RECIST

PF-06647263
 PF-06647263
Part 1
 Part 2
Best overall response, n (%) Dose escalation
N = 481 		Expansion cohort 0.015 mg/kg QW
N= 12
CR   0 0
PR   5 (10.4) 1 (8.3)
uPR   0 1 (8.3)
SD ≥126 days   8 (16.7) 1 (8.3)
SD <126 days 12 (25.0) 1 (8.3)
Disease progression   8 (16.7) 6 (50.0)
Symptomatic deterioration   0 1 (8.3)
Early death   2 (4.2) 0
Indeterminate   6 (12.5) 1 (8.3)
ORR (CR + PR)   5 (10.4) 1 (8.3) [95% exact CI 0.2–38.5]
CBR rate (CR + PR + uPR + SD ≥ 126 days) 13 (27.1) 3 (25.0) [95% exact CI 5.5–57.2]
1

Seven (14.6%) patients had no measurable disease at baseline.

Abbreviations: CBR, clinical benefit response rate; CI, confidence interval; CR, complete response; ORR, objective response rate; PR, partial response; QW, weekly; SD, stable disease; uPR, unconfirmed PR.